BIR lung cancer imaging study day

28th January 2022  13:00 - 16:40 (GMT+00:00) GMT

Virtual event – Friday 28 January 13:00-16:40 GMT
3 CPD points


This virtual study day aims to provide a review and update of all aspects of lung cancer imaging focussing on the diagnostic workflow, emphasising very much on the translational aspect of imaging studies and how their interpretation affects our patients. The programme is tailored to a multidisciplinary discussion of lung cancer imaging.

View programme here


Who should attend: Any healthcare professional who interacts with patients with lung cancer!

A special thank you to our sponsors!

  • Aidence- To find out more about Veye Lung Nodules watch this video
  • Philips- Find out more information about Philips and click here.
  • Siemens Healthineers- To find out more information about Siemens Healthineers please click here.

Registration fees:

Non-members £100

World Partner Network members £65

BIR Plan 1 members £65

BIR Plan 2 members £55

BIR International members £55

BIR Trainee members £55

BIR Retired / Student members £45



Payment for all events must be made via a debit or credit card. Invoices and PO numbers cannot be used for registration payment. If you need your hospital, Trust, or organisation to pay for registration fees please have them contact our events team at For any further inquiries please contact

If you are having issues registering for the event please create or login to your MyBIR account via this link and then register for the event after you have logged in. If you are still experiencing any issues please email 

Please ensure that you have read the events terms and conditions here, before booking onto an event. 




Advanced Accelerator Applications

Advanced Accelerator Applications, S.A. (AAA), a Novartis company, is an innovative medicines company developing targeted radioligand therapies and precision imaging radioligands for oncology. We are committed to transforming patients’ lives by leading innovation in nuclear medicine. AAA currently has over 1,000 employees working across 31 sites in 12 countries (Canada, France, Germany, Israel, Italy, the Netherlands, Poland, Portugal, Spain, Switzerland, the UK and the US). The company also has global manufacturing capabilities with 19 facilities in eight countries, and six research & development sites. For more information, please visit:

Aidence B.V.

Aidence was founded in November 2015 by Mark-Jan Harte (CEO) and Jeroen van Duffelen (CBO). Based in the Netherlands and the UK, Aidence rallies over 60 data scientists, software engineers, medical, regulatory, and business professionals to provide intelligent software for the oncology pathway. Aidence believes that data is key to improving disease prevention, management, and treatment. Their mission is to empower healthcare professionals to deliver faster, more precise diagnostics. The company's starting point is lung cancer care. Aidence's first clinical application is Veye Lung Nodules, an AI-based solution for pulmonary nodule management on chest CTs. It automatically detects, measures, classifies, and tracks the growth of pulmonary nodules as small as 3 mm, then delivers its analysis directly into the radiology workflow. The solution is certified under the EU Medical Device Regulation and can be used as a second or concurrent reader. Veye Lung Nodules is currently running in routine practice and lung cancer screening across Europe, analysing thousands of patient scans each week. Aidence is the preferred AI vendor for the NHSE Targeted Lung Health Checks. Most sites involved in the programme use Aidence's solutions to detect, assess the evolution of, and report on lung nodules.

Bayer Healthcare

Bayer’s Radiology business is well placed to be the partner of choice in helping NHS trusts to address the many challenges faced today including the increasing need for governance to demonstrate best practice and improving patient care within increasing financial constraints. With market-leading contrast media and power injector systems, Bayer is able to offer innovative patient care and with the addition of its informatics platform, it can support radiology departments in driving protocol standardisation and easily accessible audit data that enable departments to meet further challenges faced around contrast and radiation dose management. 0118 2063999

GE Healthcare Ltd

GE Healthcare is a leading provider of medical imaging, monitoring, and life science technologies. GE Healthcare enables precision health in diagnostics, therapeutics and monitoring through intelligent devices, data analytics, applications and services to help providers, researchers and life sciences companies in their mission to improve outcomes for patients around the world.

Philips Healthcare

Enabling better health and better care at lower cost Philips is a leading health technology company focused on improving people`s lives across the health continuum - from healthy living and prevention, to diagnosis, treatment and home care. Applying advanced technologies and deep clinical and consumer insights, Philips delivers integrated solutions that improve people`s health and enable better outcomes. Partnering with its customers, Philips seeks to transform how healthcare is delivered and experienced. The company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care.

Siemens Healthineers

Siemens Healthineers pioneers breakthroughs in healthcare. For everyone. Everywhere. As a leading medical technology company Siemens Healthineers is continuously developing its product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company’s foundation in in-vitro diagnostics, image-guided therapy, in-vivo diagnostics, and innovative cancer care. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers’ ability to provide high-quality, efficient care. Further information is available at